Novartis is working to execute on its turnaround plan for its Alcon vision business. But for now, sales are still on the decline. In the first quarter, Alcon net sales fell 7% from $1.4 billion. The company said it expects the unit to return to sales growth during the second half of this year--and that it ultimately expects it to have low-single-digit organic growth.
Beleaguered Novartis vision business Alcon is looking for a turnaround. It's been placing some bets on innovation to help it do so in the long term. Now, the vision care specialist has partnered with--and invested in--fluid intraocular lens implant company PowerVision. Alcon also gained an option to acquire the Belmont, CA-based startup as part of the deal.
Propeller Health knows that M&A is key to staying ahead in a competitive smart inhaler environment, and the company recently added another deal to its slate. Propeller is teaming up with remote patient monitoring outfit AMC Health to roll out a program aimed at improving drug adherence for individuals with chronic obstructive pulmonary disease (COPD).
The life sciences isn't a huge business for 3-D printing player Materialise--but it's working to change that. Its latest move is a deal with Canon Lifecare Solutions, a subsidiary of Canon Global, which will market Materialise 3-D printing to hospitals in Japan.
Seoul-based Dong-A ST has signed a new licensing deal with Tobira Therapeutics that will see it gain access to research and sell the California company's fatty liver disease treatment with its new diabetes drug in its native Korea.
Singapore's NMT Pharmaceuticals has expanded a pact with Houston-based CAO Pharmaceuticals on Phase I oncology candidate CZ-48 via agreements on research and an unspecified stock purchase by NMT into CAO.
U.K. startup Oxehealth was in prototype development phase less than a year ago after completing a successful pilot trial. Now, the Oxford University spinout has nabbed a major partner to help push its novel camera-based, vital sign monitoring technology onto the market.
CJ HealthCare Corp has signed a deal potentially worth more than $90 million with Shandong Luoxin Pharmaceutical Group to sell its new version of AstraZeneca's blockbuster digestion drug Nexium in China.
Beijing-based CANbridge Li fe Sciences has sent the Taiw an FDA an Investigational New Drug (IND) application for candidate CAN-008, a brain cancer immunotherapy hopeful that was in-licensed for China rights from Germany's Apogenix.
Shanghai-based WuXi AppTec has joined hands with Juno Therapeutics in an equal joint venture to develop new cell-based cancer immunotherapies under a new company called JW Biotechnology Solutions.